|
acquired immune deficiency syndrome |
3 |
|
china |
3 |
|
condom |
3 |
|
condom use |
3 |
|
heterosexuality |
3 |
|
hiv/aids risks |
3 |
|
human immunodeficiency virus infection |
3 |
|
men who have sex with men in china |
3 |
|
partnership type |
3 |
|
microarray |
2 |
|
bevacizumab |
1 |
|
cancer |
1 |
|
capecitabine |
1 |
|
cetuximab |
1 |
|
chemoradiotherapy |
1 |
|
chemotherapy |
1 |
|
clinical trial |
1 |
|
dasatinib |
1 |
|
diabetes |
1 |
|
discriminant analysis |
1 |
|
dosage-escalated radiotherapy |
1 |
|
epigenetics |
1 |
|
everolimus |
1 |
|
gaussian random process |
1 |
|
gene and pathway-based analysis |
1 |
|
gene expression |
1 |
|
gene expression analysis |
1 |
|
gene selection |
1 |
|
genome-wide scan |
1 |
|
gwas |
1 |
|
high dose chemoradiotherapy |
1 |
|
high-dimensional data |
1 |
|
iterative feature elimination |
1 |
|
kernel machine |
1 |
|
large p small n |
1 |
|
limited stage |
1 |
|
limited-stage small-cell lung cancer |
1 |
|
lung toxicity radiation |
1 |
|
mesothelioma |
1 |
|
metastatic colorectal cancer |
1 |
|
microarrays |
1 |
|
mixed model |
1 |
|
multiple myeloma |
1 |
|
oxaliplatin |
1 |
|
pathway |
1 |
|
pathway analysis |
1 |
|
pathway tests |
1 |
|
phase ii |
1 |
|
pneumonitis |
1 |
|
prediction validation |
1 |
|
profile likelihood |
1 |
|
radiotherapy |
1 |
|
random forest |
1 |
|
random forests |
1 |
|
random pathway effects |
1 |
|
refractory colorectal cancer |
1 |
|
regularization |
1 |
|
restricted maximum likelihood |
1 |
|
romidepsin |
1 |
|
sample size |
1 |
|
score test |
1 |
|
shrinkage |
1 |
|
single-nucleotide polymorphisms |
1 |
|
small cell lung cancer |
1 |
|
small-cell lung cancer |
1 |
|
sorafenib |
1 |
|
src |
1 |
|
src kinase |
1 |
|
survival |
1 |
|
topoisomerase inhibitor |
1 |
|
toxicity predictors |
1 |
|
tumor classification |
1 |
|
tyrosine kinase inhibitor |
1 |
|
vascular endothelial growth factor |
1 |
